Cardiovascular calcification diseases
Conditions
Interventions
Calcification group:None
Non-calcification group:None
Sponsors
Southern Medical University Southern Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Voluntary signing of an informed consent form; 2.Age >= 18; 3.Gender: No restriction; 4.The aortic valve tissue specimens were obtained from patients who underwent cardiovascular surgery at Nanfang Hospital, Southern Medical University. Among these, calcified valve or vascular specimens may be obtained from patients undergoing cardiovascular surgical procedures (such as valve replacement or thoracic or abdominal aortic aneurysm resection); non-calcified valve or vascular specimens may be obtained from patients scheduled for cardiovascular surgery (such as the BENTALL procedure for ascending aortic dissection or excess internal mammary arteries excised during coronary artery bypass grafting); 5.The calcification group (experimental group) consists of patients diagnosed with calcific cardiovascular disease, including calcific aortic stenosis, coronary artery calcification, and aortic calcification. The non-calcification group (control group) consists of patients with aortic valves showing no calcification or thickening, and those scheduled for resection of arteries or valves with no obvious calcification; 6.Patients who had undergone preoperative cardiovascular imaging evaluations (such as CT calcification scoring or cardiac echocardiography) showing no evidence of calcification, or in whom histological examination postoperatively confirmed the absence of calcification in valve or vascular tissue;
Exclusion criteria
Exclusion criteria: 1.Patients with infective endocarditis or rheumatic heart valve disease; 2.Patients with hereditary or congenital valve or vascular diseases (such as Marfan syndrome), excluding bicuspid aortic valve malformation; 3.Patients with chronic systemic inflammatory or autoimmune diseases; 4.Patients with a history of thoracic radiation therapy; 5.Patients with concurrent malignant tumors; 6.Patients with severe renal insufficiency (eGFR < 30 mL/min/1.73 m^2); 7.Patients with severe hepatic insufficiency (Child-Pugh Class C); 8.Pregnant women; 9.Patients who have participated in other interventional clinical trials within the past 3 months;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Baseline analysis of demographic data, echocardiographic indicators; | — |
Countries
China
Contacts
Public ContactZeng Qingchun
Southern Medical University Southern Hospital
Outcome results
None listed